THE BEST OF THE WEEK (25 apr – 01 mag 2022)

Therapeutics and COVID-19 - Living guideline April 2022

WHO, April 2022; www.who.int/publications

The WHO *Therapeutics and COVID-19: living guideline* contains the Organization's most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The **latest version** of this living guideline is available in <u>pdf</u> format (via the 'Download' button) and via an <u>online platform</u>, and is updated regularly as new evidence emerges.

This tenth version of the WHO living guideline now contains 17 recommendations, including two new recommendations regarding nirmatrelvir-ritonavir. No further updates to the previous existing recommendations were made in this latest version.

T. Burki

Dynamic zero COVID policy in the fight against COVID

The Lancet, Respiratory Medicine, April 2022; doi.org/10.1016/S2213-2600(22)00142-4

Abstract

On April 11, 2022, the authorities in Shanghai, China, announced that they would ease the citywide lockdown. Residents in zones that have reported no new cases of COVID-19 for 2 weeks were granted permission to leave their homes, on condition that they restrict their movements to specific areas. "After a long period of lockdown, it is understandable that people want to go out and get some air, and they need to go shopping for food and medicine and go for medical treatment", stated city health official Wu Qianyu. "But if lots of people gather in a disorderly way, it will cause hidden dangers to our epidemic prevention work."

D. Goldblatt

SARS-CoV-2: from herd immunity to hybrid immunity

Nature Reviews Immunology, April 2022; doi.org/10.1038/s41577-022-00725-0

Abstract

Herd immunity, where a pathogen can no longer efficiently spread in a population, is achieved when a large proportion of the population becomes immune, making the spread of infection from person to person unlikely and protecting those without immunity. Despite the global spread of SARS-CoV-2, the failure of virus- and vaccine-induced immunity to prevent transmission, combined with the emergence of antigenically distinct variants, has made herd immunity to SARS-CoV-2 unachievable thus far. Wheredoesthisleaveus?